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Abstract
Background Psoriasis has a serious impact on patients’ lives. However, adherence to medications is often poor,
potentially compounding the burden of disease. Identifying patients who need support with psychosocial problems, or
issues with adherence, can be complex.
Objectives We aimed to develop statements that could assist the consultation process, identifying the relative impor-
tance of factors related to effective management of psoriasis for patients.
Methods A two-stage study design was used to comprehensively identify, and assess validity of, statements describing
psoriasis impact and management issues. Both components were conducted in Canada, France, Germany, Italy, Spain,
the United Kingdom and the United States. Findings from patient observation and interviews were analysed for pattern
strength, and were then used to inform the development of statements that were quantitatively assessed using a survey.
The association of drivers towards agreement with ‘my psoriasis dictates how I lead my life’was assessed using ANOVA.
Results Fifty-six patients participated in the qualitative component, and 1,884 patients using prescription medications
completed the survey. Two thematic categories were identiﬁed; disappointment with treatments, and confusion regard-
ing psoriasis associated with a lack of direction. When assessed quantitatively, key statements associated with a strong
burden of psoriasis on patients’ lives were related to isolation, social stigma, visible symptoms, impact on activities and
feelings of hopelessness. A mixture of patient-, doctor- and treatment-related factors were among the most common
reasons for non-adherence.
Conclusion Questioning using the statements most associated with psychosocial impact and non-adherence could
help identify patients with additional support needs, and assist in overcoming adherence issues.
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Introduction
Psoriasis can have a significant impact on patients’ health-
related quality of life (HRQoL), and is often linked to depressive
symptoms.1–3 Poor self-esteem, sexual dysfunction, anxiety and
suicidal ideation have all been reported in patients with psoria-
sis.1–4 Moreover, it is now recognized that the psychosocial
impact of the disease, including feelings of stigmatization and
depression, can have an even greater impact than physical symp-
toms.1,2,5,6
Depressive symptoms associated with psoriasis have in turn
been associated with behaviour patterns that could further
impact health,1,2 including smoking, drinking and decreased
physical activity or obesity.7,8 However, identifying which
patients are in need of additional support to overcome or avoid
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such serious comorbidities can be challenging, since symptom
severity is not an accurate predictor of psychological distress.9,10
Indeed, lesion severity accounts for less than half the impact of
psoriasis on patients’ HRQoL.5
It has previously been suggested that identifying and focusing
on issues that are most important to patients might also have a
positive impact on adherence to therapy.11 Indeed, non-
adherence has been shown to occur when the patient’s
preferences, expectations and beliefs have not been considered
sufficiently in the prescribing process.12 Patients with psoriasis
often struggle to adhere to therapeutic regimens, including topi-
cal medications,13 with up to 40% not using their medication as
recommended.14 Deliberate non-adherence, due to misconcep-
tions about treatment efficacy and safety, and non-intentional
non-adherence, arising from difficulties with application and
complexities of the treatment regimen, can contribute to poor
outcomes.13,15–17
To help patients overcome the impact of psoriasis on their
lives, both psychosocial and adherence issues need to be
addressed. In this two-component, mixed-method qualitative
and quantitative study, we aimed to develop and assess key ques-
tions that could help to identify patients who are in need of
additional support for psychological or adherence issues.
Methods
A two-stage study design was used to (i) comprehensively iden-
tify issues faced by patients, as well as their current practices and
beliefs, relating to their psoriasis (qualitative component) and
then (ii) determine the applicability of the issues identified by
this necessarily small group to a much wider patient population
(quantitative component). This design was used to minimize the
influence of any preconceptions held by the investigators about
the issues that patients might face. It allowed patients themselves
to discuss and show their real-life situation, before quantitative
assessment of the issues.
The qualitative component of the study was ethnographic in
methodology. It was conducted in June 2010 among patients
with psoriasis from Canada, France, Germany, Italy, Spain, the
United Kingdom and the United States. Patients were recruited
from pre-existing databases, which were set up using conve-
nience and snowball sampling, to represent a range of demo-
graphics and psoriasis severities. They were visited by an
ethnographer, who accompanied them as they went about their
day, participating in their normal activities and documenting
their behaviours using video and photographs over an initial
4–8 h-period. Within this participant observation period, a 2-h
semi-structured interview was conducted, exploring the patient’s
psoriasis, values and needs. A quarter of the patients, who were
willing to participate further in the study, were then visited a
second time. This enabled an even more candid session due to
the pre-established rapport between patient and interviewer.
Using well-established qualitative research methods,18 observa-
tions were recorded into a photo field note template, while
coding and the objective analysis of pattern strength were per-
formed using ATLAS.ti 7 software (ATLAS.ti Scientific Software
Development GmbH, Berlin, Germany). The themes and
language identified in the qualitative component were then used
to inform the development of the quantitative survey.
For the quantitative component, adults from the same coun-
tries that were included in the qualitative component had been
recruited to join a database using a mix of telephone and online
methods, including banner adverts and direct email. Those who
indicated their willingness to participate and confirmed in initial
screening questions that they suffered from psoriasis and/or
psoriatic arthritis were subsequently invited to complete an
online survey during December 2010–January 2011. This
method of recruitment was used to ensure that those entering
the survey were not biased by knowing the subject matter
beforehand. The 68-part survey included questions on demo-
graphics, comorbidities, general self-perception, symptoms,
diagnosis of severity (using broader categories than in the quali-
tative component, to be more reflective of a doctor’s diagnosis),
relationships with health care professionals (HCPs), attitudes to
treatments (including reasons for non-adherence), attitudes to
psoriasis and information seeking.
The quantitative analyses were restricted to patients who
reported current prescription medication use. To assess the
factors that contribute to a high impact on the patients’ lives,
the contribution of drivers towards agreement with the state-
ment ‘my psoriasis dictates how I lead my life’ was assessed using
ANOVA with the F-test to compare components of the total devia-
tion (SPSS; SPSS Inc., Chicago, IL, USA). Drivers assessed
included those describing components of symptom burden,
HCP relationships, patient factors and the psychosocial impact
of psoriasis.
Reasons for non-adherence to prescription medications were
assessed by a direct question: ‘are you taking [patient’s medi-
cine] according to your doctor’s exact instructions (for example,
taking the medication at the right time, the right number of
times, the right amount)?’ Patients who indicated that they were
not adherent all of the time were asked whether any of 24 pre-
defined statements applied to them, in response to the question
‘why are you not taking your [patient’s medicine] according to
your doctor’s instructions’. Statements related to the treatment,
the doctor or the patient. The reasons for non-adherence were
ranked for topical prescription medications in this analysis
because the high number of patients using this treatment-type
gave a sufficient sample size.
Results
Qualitative component
A total of 26 men and 30 women participated in the qualitative
component, with a mean age of 42 years (range, 20–67 years).
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Of these 56 patients, 71% saw a dermatologist most often, 13% a
general practitioner (GP), 4% a combination of different medi-
cal professionals, 2% a rheumatologist and 11% were not regu-
larly seeing any doctor at that time. Prescription topical
medications were being used alone by 34% of patients. Pre-
scription topicals were used in combination with oral-,
photo- or injected- therapies or combinations of these by
4%, 9%, 7% and 4% of patients respectively. Non-topical
prescription medications were used without a prescribed topi-
cal by 9% of patients (5% oral-, 2% photo- and 2% injected-
therapies), and 34% used no prescription medication. Only
one patient (2%) did not use a prescription or over-the-
counter treatment. The mean duration of psoriasis was
16 years (range, <1–53 years). Patients reported that their
psoriasis symptoms were mild (25%), mild-moderate (18%),
moderate (29%), moderate-severe (5%) or severe (23%).
Two thematic categories were generated from the raw data
(Table 1); disappointment with treatments, and confusion
regarding psoriasis, associated with a lack of direction.
Confusion and lack of direction regarding psoriasis
Patients reported a high impact of psoriasis on their lives,
independent of their diagnosed symptom severity. Physical
symptoms, including pain, itching and bleeding, drove some
patients to desperation and impaired physical activities, while
social reactions (real or perceived) were also traumatic. The
psychological impact of psoriasis was characterized by constant
worry, a struggle for control and a fear of stress triggering symp-
toms. Patients reported that a combination of these factors led
to avoidance, limitation, hiding and isolation.
It was felt among the patients that other people do not under-
stand their disease, and could think them unhygienic. In accor-
dance with this, they considered psoriasis to be a ‘dirty’ and an
uninteresting topic for discussion, with some not talking to
friends or family about the burden of the disease. Patients felt
that doctors are unable to provide a clear diagnosis and that pre-
scriptions are automated or random. They also felt that doctors
do not understand the seriousness of psoriasis, particularly the
non-physical aspects.
Disappointment with treatments
Patients felt that topical medications were not helping their pso-
riasis to a great extent. One reason was that they had been
through a long and burdensome process with trial-and-error,
and had developed negative attitudes towards topical medica-
tions by the time they received more potent options. This led to
a loss of faith in medical topical treatments, and doctors.
Patients also expressed unrealistic expectations of their treat-
ments, and stated that their doctor had not communicated what
to expect.
Poor opinions of treatments were compounded by the time
taken to apply them, fear of side effects and undesirable features
of treatments making patients feel unclean. These features
included touch (oiliness and stickiness), smell and visibility.
However, patients were more likely to accept inconvenience
when they perceived that treatments were effective. Overall, the
high perceived burden of treatments led to sporadic use of
prescription topical medications.
Statements derived from these findings that are most relevant
to the current analysis are shown in Tables 2–4.
Quantitative component
Nearly two thousand (1,884) patients who stated that they were
currently taking prescription medications for their psoriasis
completed the quantitative survey. The mean age of these
patients was 43 years (range, 18–83 years), with 45% men and
55% women. Approximately a quarter reported stress (29%),
anxiety (27%) or depression (21%) as comorbid conditions.
Patients reported that their symptoms normally affected their
body in 77% of cases, with the scalp/ears/neck, palms/soles, flex-
ures, or nails normally affected in 73%, 37%, 32% and 20% of
cases respectively.
Most patients stated that they saw a dermatologist (52%) or
GP (41%) most often (based on 1,813 patients who answered
this question). Most (58%) also reported that they had plaque
psoriasis, with 33% uncertain of their subtype and 13% report-
ing other types. Patients reported that their doctor’s assessment
of their psoriasis was mild (31%), moderate (53%) or severe
(12%), with 5% of patients unsure. The mean number of flares
per year was nine, and mean duration of psoriasis was 15 years
(range, <1–68 years). Nearly all (92%) were using topical
prescription medications, with 23%, 10% and 7% using oral-,
photo- or injected- therapies respectively. Topical prescription
medications were used in combination with other prescription
therapies by 25% of patients.
Table 1 Key categories and property codes relevant to psoriasis
management
Thematic category Property code (characteristics)
Disappointment
with treatments
Treatments are not seen as effective
Perceived burden of treatment is
ampliﬁed
Vicious circle of low satisfaction
and adherence
Loss of trust in prescription medications
leads to cosmetic and OTC alternatives
Confusion regarding
psoriasis, associated
with a lack of direction
Tangible and emotional psoriasis costs
are substantial
Psoriasis is hidden and has no clear
identity
Patients bear the burden of psoriasis alone
Patients experience a lack of direction and
authority
OTC, over-the-counter.
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Itching was the most commonly reported physical symptom,
affecting 87% of patients. Half (54%) of the patients reporting
itch experienced problems sleeping due to itching. Most patients
(60%) responded 6–10 to ‘how much impact do you think
psoriasis has on your life’ (using a discrete visual analogue scale:
1, no impact at all; 10, extremely high impact), while 40% of
patients responded 1–5. Few patients (3%) felt that their psoria-
sis had ‘no impact at all’ (responding ‘1’), while 7% reported an
‘extremely high impact’ (responding ‘10’).
Issues raised in the qualitative component regarding worry,
hiding and concern about hygiene perceptions affected more
than half of patients (Table 2). Feelings of isolation, and impact
on activities and personal relationships were less common, but
still affected many patients (Table 2). A quarter (27%) of
patients agreed with ‘my psoriasis dictates how I lead my life’.
Statements derived from the qualitative research that were most
strongly associated with this agreement are shown in Fig. 1. Key
statements related to isolation, social stigma, visible symptoms,
impact on activities and feelings of hopelessness. In accordance
with themes raised in the qualitative component, symptom
severity was not significantly associated with agreement.
While 85% of patients expressed willingness to stay on medi-
cations for extended periods of time, many expressed unrealistic
expectations regarding medications (Table 3). In contrast with
feelings expressed during the qualitative component, the major-
ity of patients (81%) reported that they receive clear instructions
from with their doctor; however, approximately a third felt that
their doctor does not take their psoriasis seriously (Table 4).
The patterns observed in attitudes to health care provider rela-
tionships were similar for patients seeing a GP or dermatologist
most often, although scores were slightly better for patients see-
ing a dermatologist most often (Table 4).
Non-adherence to prescription medications (at least some of
the time) was reported by 46% of patients using topicals, and
25%, 35% and 18%, of patients using oral-, photo- or injected-
therapies respectively. The statements most often chosen as rea-
sons for non-adherence to topical prescription medications are
shown in Fig. 2. A mixture of patient-, doctor- and treatment-
related factors were confirmed as affecting more than 10% of
non-adherent patients in the quantitative sample, with 47% of
patients reporting that they only use their medication when they
feel it is needed.
Table 2 Patient agreement with attitudinal statements regarding
their psoriasis*
Statement Patients using
prescription
medications
(n = 1,884),
agreement (%)
I would do anything to improve my psoriasis 82
I’m worried that when I stress out too much
about my psoriasis, it further provokes my
psoriasis symptoms
72
I try to hide my psoriasis from others 66
My psoriasis makes me often wonder - why me? 51
I’m very worried that other people think I’m dirty or
unclean when they see my psoriasis
51
People think my psoriasis is contagious 49
There isn’t really anything that I can do
about my psoriasis
48
I worry constantly about my psoriasis 44
No one can understand what I’m going through 43
I often feel dirty or unclean due to my psoriasis 40
Without my psoriasis, I’d be able to enjoy a
lot of activities that I cannot enjoy now
38
My psoriasis interferes with my work life
and productivity†
34
I don’t have a lot of support from family or friends
in dealing with my psoriasis‡
34
I cannot be intimate/have sex as often as I would
like because of my psoriasis
31
My psoriasis dictates how I lead my life 27
My relationships with family, friends have been
negatively affected by my psoriasis
21
People avoid me because of my psoriasis 17
*subset of full survey shown;
†question was posed negatively; numbers have been adapted
accordingly.
‡question was posed positively; numbers have been adapted
accordingly.
Table 3 Patient agreement with attitudinal statements regarding
their treatments*
Statement Patients using
prescription
medications
(n = 1,884),
agreement (%)
I’m willing to keep switching treatments or
medications until I ﬁnd the one that works
best for my psoriasis
85
I am willing to stay on prescription medication
for extended periods of time for my psoriasis
85
I don’t mind taking a psoriasis medication
every day as long as it works
83
I expect treatments to work quickly 79
I want to control how and when my medications
are taken for my psoriasis
78
I am eager to try new treatments or medications
for my psoriasis
78
I always treat my psoriasis, whether it’s with
prescription medication or just something
I buy over-the-counter
77
I expect a cure when I try a new psoriasis
treatment
69
I only take my treatment if I experience a ﬂare-up 56
I am fearful of the side effects associated with
prescription medications for my psoriasis
55
All creams work the same, it does not matter
if it is prescribed by the doctor or not
26
*subset of full survey shown.
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Discussion
This large, multinational study has identified for the first time
the relative importance of factors related to effective manage-
ment in psoriasis using a patient-centric development process.
Traditional survey methods provide useful data, but use ques-
tions based on assumptions about the patient experience. Eluci-
dating the pattern of patient experience first minimizes the risk
of missing key issues that are important to patients, and
enhances the validity of the questions being posed. The wider
applicability of specific questions related to this experience can
then be tested quantitatively.
The importance of psychosocial and subjective factors to
patients is well established in psoriasis.19–21 However, in a lim-
ited consultation period, it has been unclear which questions to
focus on to identify areas most likely to contribute to significant
impact on a patient’s life. Our research indicates that there is a
subset of patients who are in particular need of additional
support to overcome this impact. These patients could be identi-
fied by considering the key questions with the highest influence
on the feeling that psoriasis dictates daily life: whether their pso-
riasis is ‘usually’ visible, whether they feel others understand the
effect psoriasis has had on them, whether they feel others avoid
them, whether they take any measures to hide their psoriasis,
whether they feel helpless with regards to their disease and
whether they feel unable to participate in activities. However, it
should be noted that this list is not exhaustive, since the model
accounted for 60% of the effect. Questioning whether these
statements apply to a patient could help to identify a significant
burden of psoriasis, but could also help to highlight specific
issues regarding the patient’s individual problems, beliefs and
symptoms, which could be addressed with targeted interven-
tions.
Discrepancies between doctor and patient expectations of
treatments, and factors that each group consider to be important
measures of ‘effectiveness’, have been documented by previous
studies that either use a survey approach or in-depth inter-
views.11,22 In terms of treatment, a previous in-depth qualitative
investigation in the United Kingdom identified that in addition
to factors relating to efficacy, desirability (smell, consistency,
staining), the time required for application, awareness of treat-
ment risks and patients choosing to use treatments differently
than recommended were considered components of ‘effective-
ness’ from a patient’s perspective.11 The current data show that
these factors also contributed to the likelihood that patients
Table 4 Patient agreement with attitudinal statements regarding their relationships with health care providers*
Statement Patients using prescription
medications and currently
seeing a physician
(n = 1,813),
agreement (%)
Subset who see a
GP most often
(n = 739),
agreement (%)
Subset who see
a dermatologist
most often
(n = 939),
agreement (%)
Subset who
see another
physician†most
often (n = 135),
agreement (%)
My doctor gives me clear instructions on
how to use my psoriasis treatment
81 77 83 87
I am comfortable asking my doctor about
new psoriasis treatment options that
I have heard about
81 80 82 81
My doctor takes his/her time listening to
me about my psoriasis
78 73 81 84
I trust my doctor completely when it comes
to my psoriasis
77 71 80 80
If I disagree with my doctor’s recommendations,
I am comfortable speaking to him/her about it
74 74 74 78
My doctor has helped me a lot with my psoriasis 73 69 76 77
My doctor considers which treatment would best
ﬁt my lifestyle and wishes
74 70 76 78
Nurses have a good understanding of psoriasis
treatments
54 53 54 53
My doctor keeps me informed about the latest
treatment options for my psoriasis
53 40 60 67
Nobody seems able to help me regarding
my psoriasis
35 38 35 23
My doctor does not tell me what I am supposed
to expect from my treatment
35 40 33 26
My doctor does not know which treatments work
and which ones do not work
33 38 32 22
I don’t think that my doctor takes my psoriasis
very seriously
30 35 27 22
*subset of full survey shown; †including ‘psychologist/psychiatrist’, ‘rheumatologist’, ‘alternative therapists’ or ‘other’.
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adhered to topical medications. Interestingly, half of the
non-adherent population stated that they are making a personal
choice about how to use their medicine and nearly a third
felt that they were not given sufficient explanation regarding
how to take their medicine. A recent qualitative study on self-
management experiences in psoriasis also identified that a lack
of understanding of how treatments work contributed to deci-
sions not to adhere to treatment regimens.23 This is reinforced
by the large proportion of patients in the current population
unrealistically expecting a cure and rapid results from their
treatment. These findings highlight the importance of education
for patients about treatments and how to self-manage their
condition effectively, which patients also desire and expect.23
A positive, empathetic relationship between patients and
doctors is vital in psoriasis.24 While our survey results suggest
that the majority of patients experienced this – expressing com-
fort and the feeling that sufficient time is taken to discuss their
issues – the contrasting high levels of unrealistic expectations
suggest that the right information might not be reaching
patients. It could also mean that information might be given in a
sub-optimal format. While our analysis has focussed on patient-
doctor relationships, nurses are playing an increasingly impor-
tant role in psoriasis care in many countries. A recent pilot of a
nurse-led educational programme used a combination of group
learning, action planning, take-away materials and follow-up
telephone support.25 Each component was found to be moder-
ately to very useful by participants.25 The optimal design of such
support programmes, to give the highest HRQoL benefit, will
become clearer as more and larger studies become available.
Once a baseline level of education has been established, a
positive, constructive concordance process that takes account of
the way that a patient actually uses their medicine has been rec-
ommended. In the 2005 UK National Co-ordinating Centre for
NHS Service Delivery and Organisation R&D (NCCSDO)
report, Horne et al. postulated that prescribing is a ‘therapeutic
experiment’, and the role of the prescriber is to help the patient
make an informed choice – placing responsibility on both par-
ties for designing an appropriate regimen and supporting
‘informed adherence’ to that regimen.26 This ‘appropriate’ regi-
men does not necessarily mean using medicines exactly as set
out in prescribing information. However, it is important that
patients understand how their medicines work so they are
informed enough to know what using a medicine when they
‘need to’ really means.
Forgetfulness was also a key factor in non-adherence, and
patients can be supported to overcome this problem using vali-
dated techniques such as text-messaging.27 However, it should
be noted that this type of ‘non-intentional’ non-adherence has
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been shown to be predictable to some extent by beliefs about
treatment,28 further highlighting the need for a non-judgemental
consultation approach to elucidate the real factors driving non-
adherence for each patient. Observations have been made in
smaller qualitative11 and survey-based studies29 that ‘desirability’
features of medicine and inconvenience are important to
patients. Our data confirm that these were contributors to non-
adherence for a significant proportion of patients, and should
therefore be discussed as part of the collaborative management
process.
A limitation of our study is the use of a non-population-based
quantitative sample. However, demographic features including
age30–33 and gender,3,30–32 together with comorbidities such as
depression34 are similar to those seen in previous data sets. The
population-based EUROPSO study found features including age
of psoriasis onset (30.5 years) that are largely in accordance with
our data. There were also similarities seen in prevalence of itch
(72%) and difficulties relating to sexual activities (27%).3 It
should also be noted that while 58% of patients reported plaque
psoriasis in this study, a proportion of the 33% who did not
know their subtype were also likely to fit into this category.
The design of this study differs from traditional HRQoL
assessment, since it includes a qualitative research phase to
develop questions based on themes raised by patients. Qualita-
tive research is increasingly recognized as a key first step to
unravelling complex issues caused by diseases such as psoriasis,35
but has been used to a limited extent in this field and patient
group to date. The quantitative phase of this study was used to
validate the relevance of key statements in a larger population.
However, the effectiveness of employing questions developed
from this study should be assessed by further research. Poten-
tially, the questions relating to impact on life could be employed
at a first consultation, and also during follow-up to help inform
and refine management discussions with the patient. Tools that
suggest specific support-types available in a particular country
could be a useful adjunct. The questions relating to adherence
could be used at a first follow-up after a new topical treatment is
prescribed, then at intervals for as long as the treatment contin-
ues to be prescribed.
In conclusion, specific questions relating to isolation, social
stigma, impact of psoriasis on activities and feelings of hopeless-
ness should be included in consultations. Patients should also be
helped to develop realistic expectations of newly prescribed
treatments, followed by constructive discussion of the reasons
for non-adherence over time. This approach has the potential to
maximize the chances of optimal adherence. It could also help
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to identify patients who might benefit from approaches to opti-
mize treatment effectiveness, through adherence enhancement
and related support of patient self-management and coping.
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